RecoveryResearch Phase

Thymosin Beta-4 Fragment (TB4-Frag)

Subcutaneous injection, Topical

Overview

Thymosin Beta-4 Fragment refers to bioactive segments derived from the 43-amino acid thymosin beta-4 protein, most commonly a 7-amino acid N-terminal sequence (Ac-SDKP). These fragments retain specific biological activities of the parent peptide, including modulation of actin polymerization, angiogenesis, and inflammation.

Mechanism of Action

Shorter fragments may offer improved stability and targeted activity compared to full-length thymosin beta-4..

Research Summary & Key Findings

The tetrapeptide Ac-SDKP has been studied in rodent models of fibrosis and hypertension, demonstrating anti-inflammatory and antifibrotic effects. Preclinical wound healing models have shown enhanced angiogenesis and epithelialization with various TB4 fragments. Clinical evidence in humans remains limited to small exploratory studies without large-scale controlled trials.

Clinical Status

Research Phase

Thymosin Beta-4 Fragment (TB4-Frag) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionTopical

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers Thymosin Beta-4 Fragment (TB4-Frag) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Thymosin Beta-4 Fragment (TB4-Frag).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.